Title: Evaluating the Efficacy of 8 Non-invasive Models in Predicting MASLD and Its
Progression: A Prospective Study
Version: 3 Date: 19 Aug 2024
Reviewer:  Mohamed El-Ghobary
Reviewer's report:
Thank you very much for the effort you put in that study,I appreciate a lot of effort was done,
although I have some small remarks
Last line in page 6 , how can you judge those cases if they are normal now?? And how many
cases?
“MRI-PDFF assessments indicated that some participants no longer had evidence of fatty liver
at the time of entry into the study”
Page 7 third line   sum of cases is not 100%
“(Control: N=146, 17.3%; Mild MASLD: N=400, 47.3%; Moderate MASLD: N=257, 30.4%;
Severe MASLD: N=43, 5%).”
Page 7 last paragraph, how the more severe masld is associated with less fat in liver
“The lower liver fat equation was found in severe MASLD, which was presumably due to the
relatively low rate of diabetes and MetS in this group (as the presence of MetS and diabetes was
a significant factor for the model).”
Page 9 third line :  the third goup is progression group not improve
“categorized (Improve group: N=76, 32.2%; Keep group: N=83, 35.2%; Improve group: N=77,
32.6%; Supplementary Table 2)”
Page 9
“changes in bmi and wc”   here we add – minus  ?
(-0.6 kg/m2, 0.2 kg/m2 and 0.6 kg/m2; 0.001 cm, 0.8 cm and 3.3 cm, respectively; P<0.001).
To become (-0.6 kg/m2, -0.2 kg/m2 and- 0.6 kg/m2; -0.001 cm, -0.8 cm and -3.3 cm,
respectively; P<0.001).
page 9   alt changes and ast changes were switched,  progression cases had marked decrease?
so you have to reorganize from less to more
“For biomarkers related to liver injury (change in ALT: -18.3 U/L, -4.8 U/L and 4 U/L; change
in AST: -7.8 U/L, -4.7 U/L and 1.9 U/L; change in GGT: -8.7 U/L, 0.7 U/L and 6.7 U/L,
respectively; all P<0.001)”
Title: Evaluating the Efficacy of 8 Non-invasive Models in Predicting MASLD and Its
Progression: A Prospective Study
Version: 3 Date: 19 Aug 2024
Reviewer:  Mohamed El-Ghobary
Reviewer's report:
Thank you very much for the effort you put in that study,I appreciate a lot of effort was done,
although I have some small remarks
Last line in page 6 , how can you judge those cases if they are normal now?? And how many
cases?
“MRI-PDFF assessments indicated that some participants no longer had evidence of fatty liver
at the time of entry into the study”
Page 7 third line   sum of cases is not 100%
“(Control: N=146, 17.3%; Mild MASLD: N=400, 47.3%; Moderate MASLD: N=257, 30.4%;
Severe MASLD: N=43, 5%).”
Page 7 last paragraph, how the more severe masld is associated with less fat in liver
“The lower liver fat equation was found in severe MASLD, which was presumably due to the
relatively low rate of diabetes and MetS in this group (as the presence of MetS and diabetes was
a significant factor for the model).”
Page 9 third line :  the third goup is progression group not improve
“categorized (Improve group: N=76, 32.2%; Keep group: N=83, 35.2%; Improve group: N=77,
32.6%; Supplementary Table 2)”
Page 9
“changes in bmi and wc”   here we add – minus  ?
(-0.6 kg/m2, 0.2 kg/m2 and 0.6 kg/m2; 0.001 cm, 0.8 cm and 3.3 cm, respectively; P<0.001).
To become (-0.6 kg/m2, -0.2 kg/m2 and- 0.6 kg/m2; -0.001 cm, -0.8 cm and -3.3 cm,
respectively; P<0.001).
page 9   alt changes and ast changes were switched,  progression cases had marked decrease?
so you have to reorganize from less to more
“For biomarkers related to liver injury (change in ALT: -18.3 U/L, -4.8 U/L and 4 U/L; change
in AST: -7.8 U/L, -4.7 U/L and 1.9 U/L; change in GGT: -8.7 U/L, 0.7 U/L and 6.7 U/L,
respectively; all P<0.001)”
Please review this paper.
user
Title: Evaluating the Efficacy of 8 Non-invasive Models in Predicting MASLD and Its
Progression: A Prospective Study
Version: 3 Date: 19 Aug 2024
Reviewer:  Mohamed El-Ghobary
Reviewer's report:
Thank you very much for the effort you put in that study,I appreciate a lot of effort was done,
although I have some small remarks
Last line in page 6 , how can you judge those cases if they are normal now?? And how many
cases?
“MRI-PDFF assessments indicated that some participants no longer had evidence of fatty liver
at the time of entry into the study”
Page 7 third line   sum of cases is not 100%
“(Control: N=146, 17.3%; Mild MASLD: N=400, 47.3%; Moderate MASLD: N=257, 30.4%;
Severe MASLD: N=43, 5%).”
Page 7 last paragraph, how the more severe masld is associated with less fat in liver
“The lower liver fat equation was found in severe MASLD, which was presumably due to the
relatively low rate of diabetes and MetS in this group (as the presence of MetS and diabetes was
a significant factor for the model).”
Page 9 third line :  the third goup is progression group not improve
“categorized (Improve group: N=76, 32.2%; Keep group: N=83, 35.2%; Improve group: N=77,
32.6%; Supplementary Table 2)”
Page 9
“changes in bmi and wc”   here we add – minus  ?
(-0.6 kg/m2, 0.2 kg/m2 and 0.6 kg/m2; 0.001 cm, 0.8 cm and 3.3 cm, respectively; P<0.001).
To become (-0.6 kg/m2, -0.2 kg/m2 and- 0.6 kg/m2; -0.001 cm, -0.8 cm and -3.3 cm,
respectively; P<0.001).
page 9   alt changes and ast changes were switched,  progression cases had marked decrease?
so you have to reorganize from less to more
“For biomarkers related to liver injury (change in ALT: -18.3 U/L, -4.8 U/L and 4 U/L; change
in AST: -7.8 U/L, -4.7 U/L and 1.9 U/L; change in GGT: -8.7 U/L, 0.7 U/L and 6.7 U/L,
respectively; all P<0.001)”
assistant